Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.65 |
| ▸ | MAOA | P21397 | 6/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | RXRG | P48443 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908788 | 0.83 | MAOB (0.62) | MAOBMAOANR4A2ACHE | |
| SCHEMBL1437457 | 0.83 | MAOB (0.60) | MAOBMAOAALOX5 | |
| SCHEMBL7346312 | 0.81 | MAOB (0.60) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL3624161 | 0.81 | MAOB (0.73) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL7348486 | 0.81 | MAOB (0.83) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL9946072 | 0.80 | ENPP2 (0.46) | MAOBMAOAMRGPRX4ACHE | |
| SCHEMBL16687438 | 0.80 | ENPP2 (0.59) | MAOBMAOAMRGPRX4 | |
| SCHEMBL4698486 | 0.80 | NR4A2 (0.66) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL10169470 | 0.80 | MAOB (0.71) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL22887457 | 0.79 | MRGPRX4 (0.74) | NR4A2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249106-B2 | Substituted hydrazide compounds and use thereof | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2016-02-02 | — | — | US | disclosed |
| US-9249106-B2 | Substituted hydrazide compounds and use thereof | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2016-02-02 | — | — | US | disclosed |
| EP-2468730-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND APPLICATION THEREOF | Shenyang J & Health Pharmaceutical Co., Ltd. (CN) | 2012-06-27 | — | — | EP | disclosed |
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2012-06-07 | — | — | US | disclosed |
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SHENYANG J & HEALTH PHARMACEUTICAL CO., LTD. (CN) | 2012-06-07 | — | — | US | disclosed |
| WO-2011124087-A1 | OXADIAZOLE-BASED PIPERAZINE DERIVATIVES AND APPLICATIONS THEREOF | 沈阳药科大学 (CN) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142921-A1 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | SLC5A1, VHL, AKR1A1 | MAOB 722/4885MAOA 907/4885RXRA 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.